Since 2011, the early evaluation of the benefits of new drugs has been a major challenge for pharmaceutical companies. The purpose of early benefit assessment is to negotiate prices for reimbursement amounts. The AMNOG process requires different negotiation skills and skills in order to optimize the process.
We offer trainings to prepare for:
The G-BA consultation to determine the appropriate comparative therapy and the patient relevance of the endpoints under consideration;
The Federal Joint Committee’s position and oral hearing as part of the benefit assessment and decision-making process;
The actual price negotiations for the reimbursement amount with the GKV central association.
Take advantage of our experience for optimal preparation in terms of content and communication for the important negotiations with the cost payers. Benefit from our competence in content and negotiation theory.